Skip to main content
Veterinary Medicines

Megecat 5 mg Tablet

Authorised
  • Megestrol acetate

Product identification

Medicine name:
Megecat 5 mg Tablet
Megecat 5 mg Comprimé
Megecat 5 mg Tablette
Active substance:
  • Megestrol acetate
Target species:
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Megestrol acetate
    5.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QG03AC05
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • Megecat 6 Tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Vetoquinol
Marketing authorisation date:
Manufacturing sites for batch release:
  • Vetoquinol S.A.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V133235
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 11/04/2023
French (PDF)
Published on: 11/04/2023

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 11/04/2023
French (PDF)
Published on: 11/04/2023
German (PDF)
Published on: 11/04/2023

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 11/04/2023
French (PDF)
Published on: 11/04/2023
German (PDF)
Published on: 11/04/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."